Journey Medical (DERM) Stock Price, News & Analysis

Company Overview

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Key Stats

• Today's Range: $6.11 to $6.86
• 50-Day Range: $5.00 to $7.58
• 52-Week Range: $3.20 to $7.84
• Volume: 79,472 shs
• Average Volume: 81,724 shs
• Market Capitalization: $146.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.88
• Consensus Rating: Buy

Journey Medical Stock Analysis - MarketRank™

Journey Medical scored higher than 45% of companies evaluated by MarketBeat, and ranked 644th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Journey Medical has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Journey Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Journey Medical are expected to grow in the coming year, from ($1.02) to ($0.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Journey Medical is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Journey Medical is -6.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Journey Medical has a P/B Ratio of 6.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.74% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Journey Medical has recently increased by 31.85%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Journey Medical does not currently pay a dividend.

Dividend Growth

Journey Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.74% of the float of Journey Medical has been sold short.

Short Interest Ratio / Days to Cover

Journey Medical has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Journey Medical has recently increased by 31.85%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.74

News Sentiment

Journey Medical has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Journey Medical this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for DERM on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Journey Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,229.00 in company stock.

Percentage Held by Insiders

13.16% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.25% of the stock of Journey Medical is held by institutions.

DERM Stock Analysis - Frequently Asked Questions

How have DERM shares performed this year?

Journey Medical's stock was trading at $3.91 on January 1st, 2025. Since then, DERM shares have increased by 61.6% and is now trading at $6.32.
View the best growth stocks for 2025 here.

How were Journey Medical's earnings last quarter?

Journey Medical Co. (NASDAQ:DERM) issued its quarterly earnings results on Wednesday, March, 26th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.30. The company had revenue of $14.30 million for the quarter, compared to the consensus estimate of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative trailing twelve-month return on equity of 132.10%.
Read the conference call transcript.

When did Journey Medical IPO?

Journey Medical (DERM) raised $39 million in an initial public offering (IPO) on Friday, November 12th 2021. The company issued 3,520,000 shares at $10.00-$12.00 per share.

Who are Journey Medical's major shareholders?

Journey Medical's top institutional shareholders include Cambridge Investment Research Advisors Inc. (1.46%) and Kovitz Investment Group Partners LLC (0.09%). Insiders that own company stock include Claude Maraoui, Ramsey Alloush, Lindsay A Md Rosenwald, Justin Adam Smith and Joseph Benesch.
View institutional ownership trends.

How do I buy shares of Journey Medical?

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Journey Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Journey Medical investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), ServiceNow (NOW), Adobe (ADBE) and AppLovin (APP).

Company Calendar

• Last Earnings: 3/26/2025
• Today: 5/14/2025
• Next Earnings (Estimated): 5/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DERM
• Previous Symbol: NASDAQ:DERM
• CIK: 1867066
• Web: journeymedicalcorp.com
• Phone: 480-434-6670
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $9.88
• High Stock Price Target: $11.00
• Low Stock Price Target: $9.00
• Potential Upside/Downside: +56.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,850,000.00
• Net Margins: -31.74%
• Pretax Margin: -31.52%
• Return on Equity: -132.10%
• Return on Assets: -26.90%

Debt

• Debt-to-Equity Ratio: 1.81
• Current Ratio: 1.38
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $56.13 million
• Price / Sales: 2.60
• Cash Flow: $0.22 per share
• Price / Cash Flow: 28.37
• Book Value: $1.05 per share
• Price / Book: 6.02

Miscellaneous

• Outstanding Shares: 23,104,000
• Free Float: 18,141,000
• Market Cap: $146.02 million
• Optionable: N/A
• Beta: 0.86